Want to see HK:9960 full AI Analyst Report?
Top Page
Kindstar Globalgene Technology, Inc.
(9960)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$0.90
▼(-23.16% Downside)
Action:Reiterated
Date:10/30/26
Overall score reflects a pressured core business (multi-year revenue decline and continued net losses) partially offset by a low-leverage balance sheet and a notable improvement to positive operating and free cash flow in 2025. Technicals remain bearish with the price below key moving averages and a negative MACD, while valuation is supported mainly by the high dividend yield despite loss-driven negative P/E.
Positive Factors
Conservative Balance Sheet
Low leverage and a sizable equity base provide financial resilience as the company manages its pressured operating results. This structure can reduce financing strain, preserve flexibility for laboratory investment, and improve its ability to withstand continued volatility in demand and profitability.
Negative Factors
Multi-Year Revenue Decline
Three consecutive years of revenue contraction indicate a sustained challenge in demand, pricing, or service volume rather than a single-period fluctuation. Continued top-line decline can reduce operating leverage, weaken market reach, and make a durable return to profitability more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Low leverage and a sizable equity base provide financial resilience as the company manages its pressured operating results. This structure can reduce financing strain, preserve flexibility for laboratory investment, and improve its ability to withstand continued volatility in demand and profitability.
Read all positive factors
Kindstar Globalgene Technology, Inc. (9960) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$931.99M
Dividend Yield10.61%
Average Volume (3M)183.14K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue Growth7.95%
EPS Growth60.86%
CountryHK
Employees2,999
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,041,326,700
10 Day Avg. Volume75,400
30 Day Avg. Volume183,143
Financial Highlights & Ratios
PEG Ratio-6.54
Price to Book (P/B)0.37
Price to Sales (P/S)1.07
P/FCF Ratio22.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kindstar Globalgene Technology, Inc. Business Overview & Revenue Model
Company Description
Kindstar Global (Beijing) Technology, Inc. is a prominent provider of highly specialized diagnostic services to healthcare institutions across China. Beyond just diagnostics, the company extends its expertise to support medical research, clinical ...
How the Company Makes Money
Kindstar Globalgene Technology, Inc. primarily makes money by providing fee-based clinical specialty testing services to healthcare institutions (e.g., hospitals) and other customers that outsource laboratory testing. Revenue is generally generate...
Kindstar Globalgene Technology, Inc. Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
70
Positive
Cash Flow
48
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 950.26M | 933.57M | 927.57M | 967.26M | 1.39B | 930.67M |
| Gross Profit | 432.87M | 411.38M | 439.56M | 451.13M | 603.05M | 485.77M |
| EBITDA | -44.87M | -69.21M | -90.49M | 126.38M | 150.72M | -1.39B |
| Net Income | -41.53M | -58.74M | -54.59M | 41.29M | 75.46M | -1.45B |
Balance Sheet | ||||||
| Total Assets | 3.71B | 3.76B | 3.77B | 3.67B | 3.73B | 3.19B |
| Cash, Cash Equivalents and Short-Term Investments | 1.80B | 1.56B | 1.66B | 2.03B | 2.00B | 2.15B |
| Total Debt | 394.97M | 438.12M | 398.36M | 194.29M | 199.86M | 18.19M |
| Total Liabilities | 1.07B | 969.17M | 950.51M | 774.23M | 871.62M | 464.15M |
| Stockholders Equity | 2.58B | 2.73B | 2.78B | 2.87B | 2.83B | 2.72B |
Cash Flow | ||||||
| Free Cash Flow | 138.39M | 43.60M | -179.57M | -189.65M | -102.90M | -220.23M |
| Operating Cash Flow | 182.33M | 91.17M | -44.12M | -14.78M | 21.41M | 68.03M |
| Investing Cash Flow | -112.63M | -36.85M | -1.21B | 854.92M | -1.35B | -666.06M |
| Financing Cash Flow | -131.87M | -39.49M | 144.63M | -82.83M | 97.64M | 1.59B |
Kindstar Globalgene Technology, Inc. Technical Analysis
Negative
1.17
Price Trends
0.93
Negative
0.95
Negative
1.00
Negative
Market Momentum
-0.01
Positive
46.11
Neutral
52.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9960, the sentiment is Negative. The current price of 1.17 is above the 20-day moving average (MA) of 0.91, above the 50-day MA of 0.93, and above the 200-day MA of 1.00, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 46.11 is Neutral, neither overbought nor oversold. The STOCH value of 52.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9960.
Kindstar Globalgene Technology, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$114.79B | 15.91 | 10.15% | ― | 25.80% | 35.81% | |
62 Neutral | HK$5.78B | 27.57 | 2.55% | 0.39% | 1.59% | -58.55% | |
54 Neutral | HK$6.03B | 26.41 | 1.87% | 1.87% | 6.52% | ― | |
52 Neutral | HK$1.11B | 78.10 | 0.48% | 1.10% | -3.26% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$931.99M | -18.58 | -1.56% | 10.61% | 7.95% | 60.86% | |
43 Neutral | HK$474.12M | -2.60 | -8.65% | ― | 47.93% | 65.94% |
* Healthcare Sector Average
HK:9960
Kindstar Globalgene Technology, Inc.
0.90
-0.30
-25.42%
HK:1951
Jinxin Fertility Group Ltd.
2.24
-0.17
-6.94%
HK:3886
Town Health International Medical Group Ltd.
0.16
-0.11
-39.71%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
9.42
-3.67
-28.02%
HK:6618
JD Health International, Inc.
35.98
-24.72
-40.72%
HK:2453
Concord Healthcare Group Co., Ltd. Class H
0.61
-1.94
-76.18%
Kindstar Globalgene Technology, Inc. Corporate Events
Kindstar Globalgene Narrows Loss as Oncology Testing Drives Interim Growth
Aug 26, 2026
Kindstar Globalgene Technology reported interim revenue of RMB473.6 million for the six months ended June 30, 2026, a 3.7% year-on-year increase driven by stable performance in its core hematology segment and rapid expansion in oncology testing. T...
Kindstar Globalgene Sets Board Meeting to Review Interim Results and Dividend
Aug 13, 2026
Kindstar Globalgene Technology, Inc. has scheduled a board meeting for August 26, 2026 to review and approve the group’s consolidated interim results for the six months ended June 30, 2026. The board will also consider the payment of an inte...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.